Starling Oncology, Inc. (STLN)
NASDAQ: STLN · Real-Time Price · USD
3.000
-0.180 (-5.66%)
At close: Nov 20, 2026, 4:00 PM EST
2.990
-0.010 (-0.33%)
After-hours: Nov 20, 2026, 7:30 PM EST
Starling Oncology Revenue
Starling Oncology had revenue of $169.77M in the quarter ending September 30, 2026, with 24.31% growth. This brings the company's total for the last twelve months to $620.45M, up 34.58% year-over-year. In the year 2025, Starling Oncology had annual revenue of $502.73M with 27.79% growth. That makes Starling Oncology the 10,063rd largest company in the world by revenue and 2,161st in the United States.
Revenue (ttm)
$620.45M
Revenue Growth
+34.58%
P/S Ratio
0.49
Revenue / Employee
$967,936
Employees
641
Market Cap
305.97M
Revenue by Segment
- Specialty Pharmacy 269.18M 53.5%
- Patient Services 228.99M 45.5%
- Clinical Trials & Other 4.56M 0.9%
Fiscal year ended Dec 31, 2025 See the full Starling Oncology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 502.73M | 109.32M | 27.79% |
| Dec 31, 2024 | 393.41M | 69.17M | 21.33% |
| Dec 31, 2023 | 324.24M | 71.76M | 28.42% |
| Dec 31, 2022 | 252.48M | 49.48M | 24.37% |
| Dec 31, 2021 | 203.00M | 15.49M | 8.26% |
| Dec 31, 2020 | 187.52M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Community Health Systems | 11.65B |
| GMR Solutions | 5.97B |
| Auna S.A. | 1.42B |
| The Pennant Group | 1.17B |
| InnovAge Holding | 1.02B |
| Nutex Health | 796.53M |
| WW International | 646.30M |
| Strata Critical Medical | 280.76M |
STLN News
- 12 days ago - Starling Oncology management to meet virtually with BTIG - TheFly
- 15 days ago - Starling Oncology price target lowered to $10 from $11 at B. Riley - TheFly
- 15 days ago - Starling Oncology price target lowered to $8 from $10 at Lake Street - TheFly
- 16 days ago - Starling Oncology reports Q3 EPS (13c) vs. (14c) last year - TheFly
- 16 days ago - Starling Oncology sees Q4 adjusted EBITDA $3M-$5M - TheFly
- 16 days ago - Starling Oncology narrows FY26 revenue view to $650M-$660M from $650M-$670M - TheFly
- 16 days ago - Starling Oncology Earnings Call Transcript: Q3 2026 - Transcripts
- 16 days ago - Starling Oncology Earnings release: Q3 2026 - Filings